Reimbursement for drugs — a register study comparing economic outcome for five healthcare centres in areas with different socioeconomic conditions

Abstract

Aims: Previous studies have indicated the negative effects of socioeconomic deprivation on health status and morbidity. Nevertheless, the economic assignment systems for pharmaceutical benefits in Sweden do not take socioeconomic status (SES) into account. The aim of the study was, therefore, to compare reimbursement for subsidized drugs at primary healthcare centres (HCCs) with differing socioeconomic conditions in relation to real costs. The word reimbursement is used to denote economic compensation to the HCCs from the county council for drug benefit costs. Methods: The numbers of individuals dispensed drugs, total costs and reimbursement at five HCCs with different socioeconomic conditions were compared. A socioeconomic index was calculated for each HCC on the basis of information from the municipality registries on income (with negative sign), assistance allowance, education, foreign background, and unemployment. Register data on drug benefit costs were retrieved from the National Corporation of Pharmacies (Apoteket AB) and the Swedish Prescribed Drug Register at the National Board of Health and Welfare. Data on listed and unlisted citizens at the Kalmar County Council and on public statistics from registers at the HCC municipalities where the HCCs were situated were retrieved. Results: There was an almost inverse linear relationship between total cost compensation and the socioeconomic index (n = 5; r =-0.99; p = 0.001). The HCCs with the lowest SES received lower cost compensation. Conclusions: HCCs responsible for citizens with lower SES appeared to be disadvantaged by the prevalent reimbursement system in Sweden, thereby increasing differences in the state of health of the citizens. This, in turn, hampers health preventing programmes and lifestyle interventions. An HCC-specific standardized summary of socioeconomic burden is presented.

Keywords

Reimbursement primary healthcare drug benefit socioeconomic conditions

Get full access to this article

View all access options for this article.

References

Hemstrom O. Health inequalities by wage income in Sweden: the role of work environment . Soc Sci Med 2005;61:637-47.

Loucks EB , Magnusson KT , Cook S. , Rehkopf DH , Ford ES , Berkman LF Socioeconomic position and the metabolic syndrome in early, middle, and late life: evidence from NHANES 1999-2002. Ann Epidemiol 2007;17:782-90.

Mol GD , van de Lisdonk EH , Smits JP , van den Hoogen JM , Bor JH , Westert GP A widening health gap in general practice? Socio-economic differences in morbidity between 1975 and 2000 in The Netherlands . Public Health 2005;119:616-25.

Koster A. , Bosma H. , Kempen GI , van Lenthe FJ , van Eijk JT , Mackenbach JP Socioeconomic inequalities in mobility decline in chronic disease groups (asthma/COPD, heart disease, diabetes mellitus, low back pain): only a minor role for disease severity and comorbidity. J Epidemiol Community Health 2004;58:862-9.

Power C. , Hypponen E. , Smith GD

Socioeconomic position in childhood and early adult life and risk of mortality: a prospective study of the mothers of the 1958

British birth cohort. Am J Public Health 2005;95:1396-402.

Ess SM , Schneeweiss S. , Szucs TD European healthcare policies for controlling drug expenditure. Pharmacoeconomics 2003;21:89-103.

Schneeweiss S. Reference drug programs: effectiveness and policy implications. Health Policy 2007;81:17-28.

Martikainen J. , Kivi I. , Linnosmaa I. European prices of newly launched reimbursable pharmaceuticals - a pilot study. Health Policy 2005;74:235-46.

Vogler SHC , Leopold C. , Rosian-Schikuta I. , de Joncheere K. , Layer Thomsen T. PPRI report. Vienna: European Commission, Directorate-General Health and Consumer Protection, Austrian Federal Ministry of Health, Family and Youth; 2008.

10.

Peura SRS , Kurkijärvi U. Finland Pharma Profile. Vienna: European Commission, Health and Consumer Protection Directorate-General, Austrian Ministry of Health, Family and Youth; 2007.

11.

Frostelid THT , Sveen K. , Gregersen T. , Grosvold I. Norway Pharma Profile. Vienna: European Commission, Health and Consumer Protection Directorate General, Austrian Ministry of Health, Family and Youth; 2007.

12.

Thomsen EES , Fonnesbaek Rasmussen P. Denmark Pharma Profile. Vienna: European Commission, Health and Consumer Protection Directorate-General, Austrian Ministry of Health, Family and Youth; 2008.

13.

Redman Tkhm. Sweden Pharma Profile. Vienna: European Commission, Health Consumer Protection Directorate-General, Austrian Ministry of Health, Family and Youth; 2007.

14.

Basagana X. , Sunyer J. , Kogevinas M. , Zock JP , Duran-Tauleria E. , Jarvis D. , et al. Socioeconomic status and asthma prevalence in young adults: the European Community Respiratory Health Survey. Am J Epidemiol 2004;160:178-88.

15.

Bayard-Burfield L. , Sundquist J. , Johansson SE Ethnicity, self reported psychiatric illness, and intake of psychotropic drugs in five ethnic groups in Sweden. J Epidemiol Community Health 2001;55:657-64.

16.

Brekke M. , Hjortdahl P. , Kvien TK Severity of musculoskeletal pain: relations to socioeconomic inequality. Soc Sci Med 2002 ;54:221-8.

17.

de Gaudemaris R. , Lang T. , Chatellier G. , Larabi L. , Lauwers-Cances V. , Maitre A. , et al. Socioeconomic inequalities in hypertension prevalence and care: the IHPAF Study. Hypertension 2002;39:1119-25.

18.

Gadd M. , Johansson SE , Sundquist J. , Wandell P. Morbidity in cardiovascular diseases in immigrants in Sweden. J Intern Med 2003;254:236-43.

19.

Gadd M. , Johansson SE , Sundquist J. , Wandell P. The trend of cardiovascular disease in immigrants in Sweden. Eur J Epidemiol 2005;20:755-60.

20.

Huisman M. , Kunst AE , Bopp M. , Borgan JK , Borrell C. , Costa G. , et al. Educational inequalities in cause-specific mortality in middle-aged and older men and women in eight western European populations. Lancet 2005;365: 493-500.

21.

Li X. , Sundquist J. , Sundquist K. Socioeconomic and occupational groups and risk of asthma in Sweden. Occup Med (Lond) 2008;58:161-8.

22.

Sundquist J. , Malmstrom M. , Johansson SE Cardiovascular risk factors and the neighbourhood environment: a multilevel analysis. Int J Epidemiol 1999;28:841-5.

23.

Sundquist K. , Malmstrom M. , Johansson SE Neighbourhood deprivation and incidence of coronary heart disease: a multilevel study of 2.6 million women and men in Sweden. J Epidemiol Community Health 2004;58:71-7.

24.

Dalstra JA , Kunst AE , Borrell C. , Breeze E. , Cambois E. , Costa G. , et al. Socioeconomic differences in the prevalence of common chronic diseases: an overview of eight European countries. Int J Epidemiol 2005;34:316-26.

25.

Nielsen MW , Hansen EH , Rasmussen NK Prescription and non-prescription medicine use in Denmark: association with socio-economic position. Eur J Clin Pharmacol 2003; 59:677-84.

26.

Nielsen MW , Hansen EH , Rasmussen NK Patterns of psychotropic medicine use and related diseases across educational groups: national cross-sectional survey . Eur J Clin Pharmacol 2004;60:199-204.

27.

Al-Windi A. , Elmfeldt D. , Svardsudd K. Determinants of drug utilisation in a Swedish municipality. Pharmacoepidemiol Drug Safety 2004;13:97-103.